These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10626332)

  • 1. [Anabolic therapy in patients with HIV infections].
    Gruzdev BM; Ivannikov EV; Gorbacheva ES
    Ter Arkh; 1999; 71(11):35-7. PubMed ID: 10626332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial.
    Mulligan K; Zackin R; Clark RA; Alston-Smith B; Liu T; Sattler FR; Delvers TB; Currier JS; ;
    Arch Intern Med; 2005 Mar; 165(5):578-85. PubMed ID: 15767536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting.
    Gold J; Batterham MJ; Rekers H; Harms MK; Geurts TB; Helmyr PM; Silva de Mendonça J; Falleiros Carvalho LH; Panos G; Pinchera A; Aiuti F; Lee C; Horban A; Gatell J; Phanuphak P; Prasithsirikul W; Gazzard B; Bloch M; Danner SA;
    HIV Med; 2006 Apr; 7(3):146-55. PubMed ID: 16494628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of nandrolone decanoate in wasting associated with HIV.
    Saha B; Rajadhyaksha GC; Ray SK
    J Indian Med Assoc; 2009 May; 107(5):295-9. PubMed ID: 19886384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anabolic steroids in COPD: a review and preliminary results of a randomized trial.
    Sharma S; Arneja A; McLean L; Duerksen D; Leslie W; Sciberras D; Lertzman M
    Chron Respir Dis; 2008; 5(3):169-76. PubMed ID: 18684793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment.
    Storer TW; Woodhouse LJ; Sattler F; Singh AB; Schroeder ET; Beck K; Padero M; Mac P; Yarasheski KE; Geurts P; Willemsen A; Harms MK; Bhasin S
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4474-82. PubMed ID: 15914526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of testosterone in the AIDS wasting syndrome.
    Corcoran C; Grinspoon S
    AIDS Clin Care; 1999 Apr; 11(4):25-6, 33-4. PubMed ID: 11366208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of an anabolic steroid during cytotoxic chemotherapy for metastatic cancer.
    Spiers AS; DeVita SF; Allar MJ; Richards S; Sedransk N
    J Med; 1981; 12(6):433-45. PubMed ID: 7033426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection.
    Gold J; High HA; Li Y; Michelmore H; Bodsworth NJ; Finlayson R; Furner VL; Allen BJ; Oliver CJ
    AIDS; 1996 Jun; 10(7):745-52. PubMed ID: 8805865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial.
    Johansen KL; Mulligan K; Schambelan M
    JAMA; 1999 Apr; 281(14):1275-81. PubMed ID: 10208142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-agent/combination therapy of human immunodeficiency virus-related wasting.
    Wanke C
    Semin Oncol; 1998 Apr; 25(2 Suppl 6):98-103. PubMed ID: 9625391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effects of nandrolone and testosterone in adult male HIV patients with AIDS wasting syndrome (AWS): a randomized, double-blind, placebo-controlled trial.
    Sardar P; Jha A; Roy D; Majumdar U; Guha P; Roy S; Banerjee R; Banerjee AK; Bandyopadhyay D
    HIV Clin Trials; 2010; 11(4):220-9. PubMed ID: 20974577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial.
    Johansen KL; Painter PL; Sakkas GK; Gordon P; Doyle J; Shubert T
    J Am Soc Nephrol; 2006 Aug; 17(8):2307-14. PubMed ID: 16825332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials update in human immunodeficiency virus wasting.
    Muurahainen N; Mulligan K
    Semin Oncol; 1998 Apr; 25(2 Suppl 6):104-11. PubMed ID: 9625392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Building your body to survive: the use of anabolic steroids for HIV therapy.
    Vergel N
    Posit Aware; 1998; 9(2):37-41. PubMed ID: 11365225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nandrolone decanoate reduces the premature mortality of cardiomyopathic hamsters.
    Davis WM; Long SF; Lin TL
    Res Commun Chem Pathol Pharmacol; 1993 Jul; 81(1):21-32. PubMed ID: 8210687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with nandrolone decanoate and megestrol acetate in HIV-infected men.
    Cuerda C; Zugasti A; Bretón I; Camblor M; Miralles P; García P
    Nutr Clin Pract; 2005 Feb; 20(1):93-7. PubMed ID: 16207650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutritional effect of nandrolone decanoate in predialysis patients with chronic kidney disease.
    Eiam-Ong S; Buranaosot S; Eiam-Ong S; Wathanavaha A; Pansin P
    J Ren Nutr; 2007 May; 17(3):173-8. PubMed ID: 17462549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss.
    Batterham MJ; Garsia R
    Int J Androl; 2001 Aug; 24(4):232-40. PubMed ID: 11454075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble tumour necrosis factor alpha receptor 2, a serum marker of resistance to the anabolic actions of growth hormone in subjects with HIV disease.
    Gelato MC; Mynarcik D; McNurlan MA
    Clin Sci (Lond); 2002 Jan; 102(1):85-90. PubMed ID: 11749664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.